DRUG COURTS AND MEDICAID MANAGED BEHAVIORAL HEALTH CARE

描述：(申请人摘要) 近年来，毒品法庭迅速增加，对 它们对犯罪活动的影响。从另一方面来说，人们对 为毒品法庭参与者提供的药物滥用治疗服务。AS 在最近一份国家药物滥用研究所的申请申请中指出， 这种信息的缺乏尤其令人震惊，因为 General正在经历与管理性医疗相关的变化。 方案促进(实际上是强制)获得和参与治疗 服务，管理式护理可能限制(或至少改变)药物滥用的提供 治疗服务。人们对它们之间的相互作用知之甚少。 毒品法庭和管理式医疗。这一问题对医疗补助特别感兴趣 客户，因为大多数州已经采用或计划实施托管 关心公共资助的药物滥用治疗计划。 这项修订的纵向队列研究(应用编号R01 DA 13091)将 描述毒品法庭参与者的药物滥用治疗服务，以及 比较俄勒冈州的群体罪犯(俄勒冈州有全国最古老的 毒品法庭方案)。俄勒冈州对其公共实体进行了戏剧性的改变 1995年的虐待治疗计划，当时服务医疗补助的费用被 管理型医疗(即按人头计价)。这个项目将检查罪犯的队列 在医疗补助管理保健之前和实施管理保健之后。 毒品法庭的参与者将与类似的罪犯进行比较 有资格但没有参加毒品法庭(主要是由于缺乏毒品 法院的身分)。医疗补助客户将与非医疗补助违法者进行比较。 主要的结果衡量标准将是再次逮捕率。流程措施将 包括药物滥用治疗服务的方式和范围(以及 从图表审查中收集的信息)。这一结果将对 司法系统和医疗补助政策制定者。

DESCRIPTION: (Applicant's Abstract) Drug courts have increased rapidly in recent years, as have evaluations of their impact on criminal activity. On the other hand, little is known about the substance abuse treatment services provided to drug court participants. As noted in a recent National Institute on Drug Abuse Request for Applications, this lack of information is especially striking since "drug abuse treatment in general is undergoing change related to managed care." While drug court programs facilitate (indeed mandate) access to and participation in treatment services, managed care may restrict (or at least alter) provision of drug abuse treatment services. Little if anything is known about the interaction between drug courts and managed care. This issue is of particular interest to Medicaid clients since most states have adopted or are planning to implement managed care for publicly funded drug abuse treatment programs. This revised longitudinal cohort study (application number R01 DA 13091) will describe substance abuse treatment services for drug court participants and comparison group offenders in Oregon (which has one of the country's oldest drug court programs). Oregon made a dramatic alteration to its public substance abuse treatment programs in 1995 when fee for service Medicaid was replaced by managed care (i.e., capitation). This project will examine cohorts of offenders prior to Medicaid managed care and after managed care had been implemented. Drug court participants will be compared with similar offenders who were eligible for but did not participate in drug court (chiefly due to lack of drug court capacity). Medicaid clients will be compared with non-Medicaid offenders. The chief outcome measure will be re-arrest rates. Process measures will include the modality and extent of drug abuse treatment services (as well as information gleaned from chart review). The results will be important for justice system and Medicaid policy makers.